Apellis Pharmaceuticals, Inc.
Clinical trials sponsored by Apellis Pharmaceuticals, Inc., explained in plain language.
-
New combo therapy aims to slow vision loss from dry AMD
Disease control Recruiting nowThis study tests whether adding APL 3007 to the existing drug Syfovre can better slow the progression of geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. About 240 adults aged 60 and older with the condition will receive either …
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 11:10 UTC
-
New drug aims to jumpstart transplanted kidneys in High-Risk patients
Disease control Recruiting nowThis study tests a drug called pegcetacoplan in adults who are getting a kidney transplant from a deceased donor and are at high risk for delayed graft function (when the kidney takes a while to start working). The goal is to see if the drug helps the kidney work sooner and reduc…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 14:03 UTC